The overall tone is highly positive, with discussions highlighting the drug's impressive weight loss outcomes (up to 11.2%) and its convenience as an oral medication, fueling optimism about a potential shift in obesity treatment, as exemplified by phrases like 'changing the obesity game' and 'significant weight reduction.' The tone, detailed trial references, and emphasis on real-world impact support a view of substantial influence and high engagement.
AgreementModerate agreement
Many discussions praise the results, emphasizing the drug's effectiveness and potential to revolutionize obesity treatment, often describing it as 'promising' and 'changing the game.'
InterestHigh interest
The frequent mention of detailed trial results, such as weight loss percentages and safety profiles, indicates high curiosity and concern among participants.
EngagementHigh engagement
Posts reference specific trial data, regulatory implications, and future expectations, showing deep involvement with the research and its implications.
ImpactHigh impact
Widespread excitement about the drug’s potential to replace injections with a simple pill suggests it could significantly influence obesity therapy and public health practices.
Abstract in brief
Orforglipron, an oral GLP-1 receptor agonist, is being tested for weight loss in adults with obesity, showing promising results in a phase 3 trial over 72 weeks.
Patients taking higher doses of orforglipron (36 mg) lost an average of 11.2% of their body weight, compared to only 2.1% loss in the placebo group, with many achieving significant weight reductions.
While adverse events were noted, primarily gastrointestinal issues, they were mostly mild to moderate, with a higher discontinuation rate in the orforglipron groups compared to placebo.
Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) https://t.co/avDbBYKZDr
#Endocrinology https://t.co/xFALCq2XqV
Nov 12, 2025 · 108 likes · 25 shares · 931,969 followersView post →
TL
The Lancet
@TheLancet · X
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial https://t.co/ElGCZnxmHB
Nov 25, 2025 · 106 likes · 30 shares · 734,029 followersView post →
N
NEJM
@NEJM · X
Here are three Original Articles from September that made big news:
1️⃣ Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 trial) https://t.co/avDbBYKZDr
Oct 3, 2025 · 96 likes · 18 shares · 931,969 followersView post →
AM
Ahmed Bennis MD
@drbennisahmed · X
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 https://t.co/EdAknfDkki
Nov 28, 2025 · 75 likes · 20 shares · 3,153 followersView post →
CT
Cristina Tejera
@cristinatejerap · X
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/GNhaj2cf7G this week in @NEJM
Nov 6, 2025 · 73 likes · 21 shares · 11,604 followersView post →
SH
Samuel Hume
@DrSamuelBHume · X
Here are the sources:
1. Oral obesity drugs: https://t.co/91u4a6BLRt, https://t.co/21Z8Gg2C1X
2. Aspirin after colorectal cancer surgery https://t.co/KrGnVtz4jz
3. Trikafta in cystic fibrosis https://t.co/zd1vgzbask
4. Apple watch detects hypertension https://t.co/MTHhO5oCfH
A bold trial in valvular heart disease and a cardiovascular prevention trial highlight the importance of humility in medical practice. Discussing new approaches to TAVI, CV risk management, and the impact of full…
Orforglipron, an oral GLP-1 receptor agonist, is showing promising weight loss results in phase 3 trials, with higher doses achieving significant body weight reduction. Mild to moderate side effects were reported…
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treat…
Nov 30, 2025 · 20 shares · 359 followersView post →
DJ
Dr.AMiT JAiSWAL
@aadvikmedics · X
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treat…
Nov 29, 2025 · 20 shares · 62 followersView post →
A
Almansour
@malmansour81 · X
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treat…
Nov 29, 2025 · 20 shares · 214 followersView post →
ER
Elvis Amao Ruiz
@elvisjar · X
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treat…
Nov 29, 2025 · 20 shares · 255 followersView post →
DM
Dr Celestino Gutiérrez González MD
@CelestinoGutirr · X
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treat…
Nov 29, 2025 · 20 shares · 11,329 followersView post →
AM
Adipose Tissue: The Circadian clock of Metabolism
@Prashan69344151 · X
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treat…
Nov 29, 2025 · 20 shares · 55 followersView post →
LC
Luis Eduardo Celi C.
@luchitoceli · X
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treat…
Nov 29, 2025 · 20 shares · 165 followersView post →
JM
Jesse Haven, MD
@jhaven99 · X
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treat…
Nov 29, 2025 · 20 shares · 121 followersView post →
DK
Dr Ashish Kumar
@DrAshish_Kumar · X
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treat…
Nov 29, 2025 · 20 shares · 19,260 followersView post →
IP
Ilenia Pantano
@PantanoIlenia · X
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treat…
Nov 29, 2025 · 20 shares · 92 followersView post →
NH
Nada Hassib
@NadaHassib1 · X
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treat…
Nov 29, 2025 · 20 shares · 764 followersView post →
S
sophia
@sophia8666ac · X
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treat…
Nov 28, 2025 · 20 shares · 1,581 followersView post →
AM
Ashley Wei MD
@AshleyWeiMD · X
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treat…
Nov 28, 2025 · 20 shares · 713 followersView post →
AW
Anna wei
@yxmfn55642275 · X
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treat…
Nov 28, 2025 · 20 shares · 425 followersView post →
S
Sherif
@Sherifdotcom · X
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treat…
Nov 28, 2025 · 20 shares · 136 followersView post →
KD
Karl Dujardin
@KDujardin · X
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treat…
Nov 28, 2025 · 20 shares · 662 followersView post →
O
Ondo(✸,✸)
@ArianaPantasy · X
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treat…
Nov 28, 2025 · 20 shares · 676 followersView post →
BF
Biljana Parapid, MD, PhD, FESC
@biljana_parapid · X
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treat…
Nov 28, 2025 · 20 shares · 8,632 followersView post →
AM
Ahmed Bennis MD
@drbennisahmed · X
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 https://t.co/EdAknfDkki
Nov 28, 2025 · 75 likes · 20 shares · 3,153 followersView post →
Z
Zoey
@Zoeynzyjo1122 · X
RT @EricTopol: Big randomized trial of a GLP- pill (vs placebo) achieves significant weight loss
https://t.co/DwMDkvsXg7 @NEJM https://t.co…
Nov 26, 2025 · 70 shares · 1,297 followersView post →
DC
Dr Chris Duncombe CMO
@DrDuncombe · X
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Nov 26, 2025 · 30 shares · 332 followersView post →
GD
Gary Deed
@garydeed · X
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Nov 26, 2025 · 30 shares · 115 followersView post →
DD
D.Dash
@dr_debu · X
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Nov 26, 2025 · 30 shares · 91 followersView post →
DD
Dr Ashok Dalal
@DrAshokGastro · X
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Nov 26, 2025 · 30 shares · 1,475 followersView post →
VB
Vikas bhargava
@Vikasbh40772075 · X
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Nov 26, 2025 · 30 shares · 16 followersView post →
MM
Mehdi Maanaoui
@MaanaouiMehdi · X
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Nov 26, 2025 · 30 shares · 999 followersView post →
JY
Javier Escalada #Yoelijoendocrino
@fjavesc · X
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Nov 26, 2025 · 30 shares · 3,631 followersView post →
A
AngryPhDstudent❗️❗️❗️
@ONNESHA092 · X
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Nov 25, 2025 · 30 shares · 197 followersView post →
CP
Carlos Palacio
@CAPE1223 · X
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Nov 25, 2025 · 30 shares · 1,023 followersView post →
E
ElenaJerezLanza
@helejtf · X
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Nov 25, 2025 · 30 shares · 31 followersView post →
TR
Thomas Round
@drtomround · X
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Nov 25, 2025 · 30 shares · 3,424 followersView post →
MP
María Argente Pla
@ArgentePla · X
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Nov 25, 2025 · 30 shares · 467 followersView post →
IT
Instructor TX
@InstructorTX · X
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. https://t.co/mgXNdNFFqL
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Nov 25, 2025 · 30 shares · 19,260 followersView post →
JC
Juan Carlos
@carlos1184 · X
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Nov 25, 2025 · 30 shares · 1,543 followersView post →
DD
darcy darnoc
@darcydarnoc · X
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Nov 25, 2025 · 30 shares · 3,149 followersView post →
DA
Dr. Jorge Acosta
@DocJorgeAcosta · X
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Nov 25, 2025 · 30 shares · 15,426 followersView post →
NF
Nicolas Renna, MD PhD ISHF FESC
@nicolasrennamd · X
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Nov 25, 2025 · 30 shares · 932 followersView post →
AR
Arshad Rashid
@arshadkema · X
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial - The Lancet https://t.co/qeiVoRpYfR
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Nov 25, 2025 · 30 shares · 53,037 followersView post →
Sシ
syawal™ シ
@syawal · X
RT @TheLancet: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (AT…
Nov 25, 2025 · 30 shares · 3,095 followersView post →
TL
The Lancet
@TheLancet · X
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial https://t.co/ElGCZnxmHB
Nov 25, 2025 · 106 likes · 30 shares · 734,029 followersView post →
SG
Shicheng Guo
@shihcheng.bsky.social · Bluesky
Orforglipron, a once-daily oral GLP-1 agonist, shows promise for obesity. Tested 6mg, 12mg, 36mg vs. placebo in a 72-week study. Outcomes look positive! PMID:40960239, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2511774 #Medsky #Pharmsky #RNA #ASHG #ESHG
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind.
Orforglipron, in people with diabetes and obesity shows significant weight loss. https://t.co/mgXNdNFFqL
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
https://t.co/BkWNPBcty8
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
"We aimed to evaluate orforglipron, an oral small-molecule
Nov 20, 2025 · 9 likes · 1 share · 43,178 followersView post →
J
Jessica
@Jessica27511l · X
RT @alexanderperse: I wonder if patient census in hospitals will go down due to this. Absolutely insane
https://t.co/l1Hh3Uw0UU
Orforglipron significantly reduces body weight in obesity patients, outperforming placebo and showing favorable safety profile over 72 weeks.
by Wharton S, Aronne LJ (...) Klise SR et 10 al. in N Engl J Med #MedSky
Orforglipron significantly reduces body weight in obesity patients, outperforming placebo and showing favorable safety profile over 72 weeks.
by Wharton S, Aronne LJ (...) Klise SR et 10 al. in N Engl J Med
https://t.co/OMCh2O5F2z #MedX #MedResearch
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Nov 14, 2025 · 25 shares · 159 followersView post →
IT
Instructor TX
@InstructorTX · X
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
This new drug is way more effective for dropping pounds, and the best part is it's just a pill you swallow!
Read. https://t.co/ggGKN8l1YK
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Nov 14, 2025 · 25 shares · 6,439 followersView post →
IN
Int Society of Nephrology
@ISNkidneycare · X
8/
Nov 13, 2025 · 6 likes · 29,483 followersView post →
CP
Carlos Palacio
@CAPE1223 · X
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Nov 13, 2025 · 25 shares · 1,023 followersView post →
DM
Dr.Lama Amer, MD
@Dr_Lama_Amer · X
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Nov 13, 2025 · 25 shares · 4,294 followersView post →
MT
Miguel Turégano
@tureyedro · X
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Nov 13, 2025 · 25 shares · 816 followersView post →
JM
Janet Chiang, MD
@JanetMD87 · X
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Nov 13, 2025 · 25 shares · 810 followersView post →
JR
John Rodriguez
@rodrig39386 · X
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Nov 13, 2025 · 25 shares · 967 followersView post →
SX
Stavra Xanthakos
@DrStavra · X
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Nov 13, 2025 · 25 shares · 322 followersView post →
BF
Biljana Parapid, MD, PhD, FESC
@biljana_parapid · X
RT @drbennisahmed: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treat…
Nov 13, 2025 · 2 shares · 8,632 followersView post →
PF
Pawan Rao MD, FASN
@nephronus · X
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Nov 13, 2025 · 25 shares · 1,009 followersView post →
MR
Maria Jesus Gonzalez Rellan
@ChusaGzlzRellan · X
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Nov 13, 2025 · 25 shares · 795 followersView post →
JC
Javier Carrera
@Javier_CarreraH · X
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Nov 13, 2025 · 25 shares · 1,833 followersView post →
SP
Sá Peliteiro
@Peliteiro · X
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Nov 13, 2025 · 25 shares · 2,866 followersView post →
DB
Dan Baciu
@fnz4sgr5jc · X
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Nov 13, 2025 · 25 shares · 51 followersView post →
DG
DIEGO FERNANDEZ GARCIA
@diegofe21784801 · X
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Nov 13, 2025 · 25 shares · 1,646 followersView post →
AM
Ahmed Bennis MD
@drbennisahmed · X
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 https://t.co/rDlejWVqyO
Nov 13, 2025 · 9 likes · 2 shares · 3,153 followersView post →
WM
Wendy Trejo MD., MSc.
@md_wentrejo · X
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Nov 13, 2025 · 25 shares · 429 followersView post →
A
AngryPhDstudent❗️❗️❗️
@ONNESHA092 · X
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Nov 12, 2025 · 25 shares · 197 followersView post →
GP
GLASS_PhD
@joybeingfree99 · X
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Nov 12, 2025 · 25 shares · 6,625 followersView post →
DA
Dr. Nasreen Alfaris
@nasreenalfaris · X
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Nov 12, 2025 · 25 shares · 2,275 followersView post →
N
nephronking
@nephronking · X
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Nov 12, 2025 · 25 shares · 133 followersView post →
PM
Peter Edmonds MD
@pjedmonds · X
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Nov 12, 2025 · 25 shares · 1,032 followersView post →
DS
@docbio.bsky.social
@DocBio1509 · X
RT @NEJM: Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) http…
Nov 12, 2025 · 25 shares · 460 followersView post →
N
NEJM
@NEJM · X
Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 phase 3 trial) https://t.co/avDbBYKZDr
#Endocrinology https://t.co/xFALCq2XqV
Nov 12, 2025 · 108 likes · 25 shares · 931,969 followersView post →
In the ATTAIN-1 phase 3, randomized trial, the use of orforglipron, an oral glucagon-like peptide-1 receptor agonist, led to significant mean body-weight reductions in patients with #obesity, as compared with placebo. Full trial results and Research Summary: nej.md/4n1nSl2
#MedSky #EndoSky
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Nov 6, 2025 · 21 shares · 178 followersView post →
CT
Cristina Tejera
@cristinatejerap · X
RT @ValleAlfonso: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity
Nov 6, 2025 · 9 shares · 11,604 followersView post →
CM
Cristobal Morales
@CristobMorales · X
RT @ValleAlfonso: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity
Nov 6, 2025 · 9 shares · 17,185 followersView post →
AV
Alfonso Valle
@ValleAlfonso · X
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity
Nov 6, 2025 · 15 likes · 9 shares · 21,708 followersView post →
AM
Andrew J Sauer MD
@AndrewJSauer · X
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Nov 6, 2025 · 21 shares · 19,603 followersView post →
W
Wimen
@1a31551c566e43d · X
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Nov 6, 2025 · 21 shares · 672 followersView post →
RM
Ranganath Muniyappa
@dr_muniyappa · X
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Nov 6, 2025 · 21 shares · 1,094 followersView post →
AG
Andy Grannell
@Grannell_ · X
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Nov 6, 2025 · 21 shares · 991 followersView post →
BV
Blad Villavicencio
@bladDV · X
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Nov 6, 2025 · 21 shares · 820 followersView post →
M
mdjungle
@mdjungle1 · X
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Nov 6, 2025 · 21 shares · 114 followersView post →
DA
Dr. Nasreen Alfaris
@nasreenalfaris · X
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Nov 6, 2025 · 21 shares · 2,275 followersView post →
CP
Carlos Palacio
@CAPE1223 · X
RT @cristinatejerap: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine ht…
Nov 6, 2025 · 21 shares · 1,023 followersView post →
BM
BaladoCritique : club de lecture médical
@baladocritique.bsky.social · Bluesky
“Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.”
Publié ce jour dans le @nejm.org.
#MedSky #EndoSky
www.nejm.org/doi/full/10....
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https://t.co/GNhaj2cf7G this week in @NEJM
Nov 6, 2025 · 73 likes · 21 shares · 11,604 followersView post →
MR
Marc Vincent Barcelona, MD, FPCR, DPBR-RO
@MarcBarcieMD · X
RT @VivekSubbiah: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https…
RT @VivekSubbiah: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https…
Nov 5, 2025 · 4 shares · 3,890 followersView post →
UD
Umut. Dişel
@UmutDisel · X
RT @VivekSubbiah: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | New England Journal of Medicine https…
Nov 5, 2025 · 4 shares · 1,281 followersView post →
PB
Prof. Dr. Sanjeev Bagai
@BagaiDr · X
Orforglipron, Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Rx. mean change in body weight from baseline to week 72 was −7.5% with 6 mg of orforglipron, −8.4% with 12 mg of orforglipron,& −11.2% with 36 mg of orforglipron,vs −2.1% with placebo https://t.co/lYOuJqpnO6
RT @EricTopol: Big randomized trial of a GLP- pill (vs placebo) achieves significant weight loss
https://t.co/DwMDkvsXg7 @NEJM https://t.co…
Oct 23, 2025 · 70 shares · 29 followersView post →
PB
Prof. Dr. Sanjeev Bagai
@BagaiDr · X
Orforglipron, Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | NEJM. 3127 patients. mean change in body weight from baseline to week 72 was −7.5%, −8.2 to −6.8 with 6 mg of orforglipron, −8.4% with 12 mg of orforglipron, https://t.co/lYOuJqpnO6
Here are three Original Articles from September that made big news:
1️⃣ Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1 trial) https://t.co/avDbBYKZDr
Oct 3, 2025 · 96 likes · 18 shares · 931,969 followersView post →
LU
Lilly Medical US
@LillyMedical · X
New Results from the ATTAIN-1 Phase 3 Trial: An Oral Small Molecule GLP-1 Receptor Agonist for Obesity Treatment.
Click here to read the full results: https://t.co/HPqVcoKZ5Y https://t.co/hA4IrxqD0v
Sep 30, 2025 · 1 like · 8,177 followersView post →
Orforglipron significantly reduces body weight in adults with obesity, outperforming placebo, while maintaining a tolerable safety profile.
by Wharton S, Aronne LJ (...) Klise SR et 10 al. in N Engl J Med #MedSky
Orforglipron significantly reduces body weight in adults with obesity, outperforming placebo, while maintaining a tolerable safety profile.
by Wharton S, Aronne LJ (...) Klise SR et 10 al. in N Engl J Med
https://t.co/OMCh2O5F2z #MedX #MedResearch
We are proud to celebrate Dr. @SeanWharton, a founding member of BPAO, for publishing two groundbreaking studies in the New England Journal of Medicine on obesity treatment.
Sep 25, 2025 · 1 like · 1,801 followersView post →
GG
geneXplain GmbH
@geneXplain · X
A groundbreaking international trial has revealed an oral drug called orforglipron that’s changing the obesity game. Unlike current injectable therapies, this is a once daily pill and its results are stunning.
#OralTherapy #WeightLossScience #ScienceIsGood https://t.co/kk7vSNA9Ki https://t.co/K4Fqo8ZOXs
¿Inicio de una nueva era en el tto de la obesidad?
Orforglipron podría cambiar el acceso a terapias GLP1:
✔️Vía de adm oral diaria
✔️Sin necesidad de conservación especial
✔️Mejorando la adherencia y biodisponibilidad
✔️Eficacia clínicamente relevante
https://t.co/Hxofi8F6aK
Sep 21, 2025 · 1 like · 2 shares · 3,349 followersView post →
DK
Dymkó Křepelka
@3dattempt · X
RT @NutrioSci: In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than plac…
In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists. @NEJM
https://t.co/L9C3AGaFH7 https://t.co/m0AL980VUt
Here are the sources:
1. Oral obesity drugs: https://t.co/91u4a6BLRt, https://t.co/21Z8Gg2C1X
2. Aspirin after colorectal cancer surgery https://t.co/KrGnVtz4jz
3. Trikafta in cystic fibrosis https://t.co/zd1vgzbask
4. Apple watch detects hypertension https://t.co/MTHhO5oCfH
In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists https://t.co/LvCFmJhA1z
“Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.””
Publié ce jour dans le @nejm.org.
#MedSky #EndoSky
www.nejm.org/doi/full/10....
Orforglipron, an oral small-molecule GLP-1 agonist, significantly lowered blood glucose compared with placebo in a phase III trial.
Read more on MIMS Pharma
Aquí te dejamos el artículo. Jastreboff AM et al. Orforglipron for the Treatment of Obesity without Diabetes. N Engl J Med. 2025; DOI: 10.1056/NEJMoa2511774 # ...
[लेख] ओरफ़ोर्ग्लीप्रोन, मोटापे के इलाज के लिए एक ओरल स्मॉल-मॉलिक्यूल ...
Reddit
अपवोट करें 1 डाउनवोट करें 2 टिप्पणियों पर जाएँ शेयर करें. कमेंट सेक्शन. u/Hot_Store2689 अवतार · Hot_Store2689. • 23 दिन पहले. Profile Badge for the Achievement Top ...
N
TL
AM
CT
SH
NP
DJ
A
ER
DM
AM
LC
JM
DK
IP
NH
S
AM
AW
S
KD
O
BF
Z
DC
GD
DD
DD
VB
FH
MM
JY
A
CP
E
TR
MP
IT
JC
DD
DA
NF
AR
JP
MH
DM
TR
JC
IL
TE
Sシ
SG
KW
DD
A
J
SR
AF
DR
KA
D
IN
MT
JM
JR
SX
PF
MR
SP
DB
DG
WM
GP
DA
N
PM
DS
S
AC
HI
弓Y
医
BA
EC
S
MT
JA
RG
JQ
HE
DS
SB
DG
J
DS
A
RL
CM
AV
AM
W
RM
AG
BV
M
V
RC
J
FL
NA
S
RP
MR
ES
UD
PB
DD
VM
LP
AL
AL
P
L
MS
Z
PH
DJ
J
U
M
FT
土
LU
さ元
BO
GG
サ
JC
MH
TT
TM
D
FS
GS
DK
MA
KN
JP
NS
TT
RK
DR
HF
SH
DC
AG
あ便
AO
JA
PL
MA
JN
MH
B
やア
MM